Korro Bio, Inc. Restricted Cash, Current
Korro Bio, Inc. (KRRO) had Restricted Cash, Current of $0 as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:RestrictedCashCurrent · last filed 2026-08-06
- 2026-06-30: Restricted Cash, Current $0.00.
- 2026-03-31: Restricted Cash, Current $1.00M.
- 2025-12-31: Restricted Cash, Current $1.00M.
- 2025-09-30: Restricted Cash, Current $1.00M.
| Period end | Restricted Cash, Current |
|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-06 |
| 2026-03-31 | $1.00M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $1.00M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $1.00M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $1.00M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-07 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-12 |
| 2024-09-30 | $1.77M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $1.77M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $3.55M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $3.56M 10-K · filed 2025-03-18 |
| 2022-12-31 | $603.00K 10-K · filed 2024-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |